- Home
- LPRO vs TVRD Comparison
LPRO vs TVRD Comparison
Compare LPRO & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- TVRD
- Stock Information
- Founded
- LPRO 2000
- TVRD 2017
- Country
- LPRO United States
- TVRD United States
- Employees
- LPRO N/A
- TVRD N/A
- Industry
- LPRO Finance: Consumer Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- TVRD Health Care
- Exchange
- LPRO Nasdaq
- TVRD Nasdaq
- Market Cap
- LPRO 252.9M
- TVRD 246.5M
- IPO Year
- LPRO N/A
- TVRD N/A
- Fundamental
- Price
- LPRO $1.85
- TVRD $4.55
- Analyst Decision
- LPRO Buy
- TVRD Buy
- Analyst Count
- LPRO 6
- TVRD 7
- Target Price
- LPRO $3.00
- TVRD $51.67
- AVG Volume (30 Days)
- LPRO 726.4K
- TVRD 708.2K
- Earning Date
- LPRO 11-06-2025
- TVRD 11-21-2025
- Dividend Yield
- LPRO N/A
- TVRD N/A
- EPS Growth
- LPRO N/A
- TVRD N/A
- EPS
- LPRO N/A
- TVRD N/A
- Revenue
- LPRO $16,254,999.00
- TVRD N/A
- Revenue This Year
- LPRO $306.78
- TVRD N/A
- Revenue Next Year
- LPRO $11.69
- TVRD N/A
- P/E Ratio
- LPRO N/A
- TVRD N/A
- Revenue Growth
- LPRO N/A
- TVRD N/A
- 52 Week Low
- LPRO $0.70
- TVRD $4.48
- 52 Week High
- LPRO $6.92
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- LPRO 43.72
- TVRD 19.70
- Support Level
- LPRO $1.78
- TVRD $4.63
- Resistance Level
- LPRO $2.01
- TVRD $5.00
- Average True Range (ATR)
- LPRO 0.14
- TVRD 0.46
- MACD
- LPRO 0.01
- TVRD -0.00
- Stochastic Oscillator
- LPRO 29.17
- TVRD 5.66
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.